Presentazione di PowerPoint
Davide Capodanno on Twitter: "#PIONEER, #REDUAL, #AUGUSTUS, and #ENTRUST in a nutshell: The Fab Four in #AF #PCI https://t.co/ve7enVHwM7" / Twitter
JCM | Free Full-Text | Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
RE-DUAL PCI, ESC 2017: Q&A with Dr. Christopher Cannon | boehringerone.com
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
PCRonline - The RE-DUAL PCI trial subanalysis: In spite of... | Facebook
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review - ScienceDirect
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial | SpringerLink
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review - ScienceDirect
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
Comparison of Safety Outcomes Between Dual Antithrombotic Therapy with Dabigatran and Triple Antithrombotic Therapy with Vitamin K Antagonist Stratified by the Presence of Clinical and/or Procedural Complexity Factors in the REDUAL PCI
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download
RE-DUAL PCI Trial: Inclusion and Main Exclusion Criteria and Study Design | Radcliffe Cardiology
Randomised controlled trials ranked by time from index event to onset... | Download Scientific Diagram
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
RE-DUAL PCI™ vs PIONEER AF-PCI™
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice | tctmd.com
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients With Atrial Fibrillation and Diabetes | JACC: Cardiovascular Interventions
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
RE-DUAL PCI™ vs PIONEER AF-PCI™
Cardiorrenal.es | ACOD - Evidencia Científica - Fibrilación Auricular - Subanálisis REDUAL PCI LIP 2019
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? | Semantic
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
